Shares of Tempus AI (TEM) surged 5.32% in pre-market trading on Monday following the company's announcement of a groundbreaking new product in cancer treatment monitoring. The biotechnology firm introduced xM, an innovative liquid biopsy assay designed to enhance the monitoring of immunotherapy response in patients with advanced cancers.

The newly unveiled xM for treatment response monitoring (TRM) is specifically engineered to detect molecular responses to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. This assay represents a significant addition to Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease (MRD) in cancer patients. While currently available for research use only, Tempus anticipates making the assay clinically available later this year, potentially opening up new revenue streams for the company.

Investors appear enthusiastic about the potential impact of this new technology on cancer treatment strategies. The xM for TRM assay's ability to track changes in circulating tumor DNA (ctDNA) dynamics over time could provide clinicians with valuable early assessments of treatment efficacy. Furthermore, Tempus has announced plans to present new data on xM for TRM at the upcoming 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, which could further validate the assay's potential and drive additional investor interest. As personalized medicine and advanced cancer treatments continue to evolve, Tempus AI's latest innovation positions the company at the forefront of this rapidly growing market segment.